Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933822 | 0.82 | TP53 (0.56) | TP53MEN1KMT2A | |
| SCHEMBL13307565 | 0.81 | POLB (0.58) | CYP1A2CYP2C9CYP2C19L3MBTL1MEN1 | |
| SCHEMBL19926859 | 0.80 | PTGS2 (0.54) | — | |
| SCHEMBL19933823 | 0.79 | KDM4E (0.43) | ALDH1A1 | |
| SCHEMBL19933819 | 0.77 | TP53 (0.52) | TP53 | |
| SCHEMBL5966710 | 0.77 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19CYP19A1ALDH1A1 | |
| SCHEMBL13307642 | 0.76 | POLB (0.52) | CYP19A1L3MBTL1MEN1KMT2A | |
| SCHEMBL19933959 | 0.76 | TP53 (0.52) | TP53KMT2A | |
| SCHEMBL13307632 | 0.76 | MAPT (0.55) | L3MBTL1MEN1KMT2A | |
| SCHEMBL5326323 | 0.75 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293773-B2 | 1, 2, 3-triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-10-23 | — | — | US | disclosed |
| US-8293773-B2 | 1, 2, 3-triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-10-23 | — | — | US | disclosed |
| US-20100144734-A1 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20100144734-A1 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144734-A1 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists | CNR1, CNR2, GPR3 | CYP1A2 807/4885CYP2C9 906/4885CYP2C19 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.